Results 151 to 160 of about 15,663 (264)

Homocitrullinated Peptides Drive Pro‐Inflammatory T Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Anti‐homocitrullinated protein/peptide antibodies are specific to rheumatoid arthritis (RA) and predictive of worse prognosis, suggesting a pathogenic role for autoreactivity to homocitrullinated peptides (HomoCitP). However, T cell responses to HomoCitP remain largely unexplored.
Sofya Ulanova, Jaspreet Kaur, Gabrielle Buckley, S. M. Mansour Haeryfar, Lisa Cameron, Ewa Cairns, Lillian Barra   +6 more
wiley   +1 more source

In Silico Study of Anti-CD40 DNA Aptamers as Vaccine Adjuvants for Chickens. [PDF]

Int J Mol Sci
Aceves-Hernández JM, Uribe Diaz S, Omolewu A, Al-Ogaili AS, Castellanos I, Vazquez MIN, Miramontes Salinas AA, Tellez-Isaia G, Kwon YM.   +8 more
europepmc   +1 more source

Immunoinformatics‐Based Design of a Multi‐Epitope Vaccine Targeting a Conserved Copper–Associated Protein in Neisseria gonorrhoeae

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Neisseria gonorrhoeae poses an urgent public health challenge due to rapidly increasing antimicrobial resistance and the absence of an effective vaccine. Targeting conserved bacterial pathways involved in essential physiological processes may provide new opportunities for vaccine antigen discovery.
Sinethemba H. Yakobi, Uchechukwu U. Nwodo   +1 more
wiley   +1 more source

Editorial: Rhinitis and pollution. [PDF]

Front Allergy
Chong-Neto HJ, Gómez RM.
europepmc   +1 more source

Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva, Caio Patrício de Souza Sena, Davi Serradella Vieira, Magdi E. A. Zaki, Leow Chiuan Yee, Shahina Akter, Umberto Laino Fulco, Jonas Ivan Nobre Oliveira, João Firmino Rodrigues‐Neto   +8 more
wiley   +1 more source

Peptide nanofibers and PAMP agonist combinations enhance pulmonary CD4⁺T cell functionality of immune recall to vaccination. [PDF]

J Nanobiotechnology
Files MA, Das A, Kim D, Buck J, Endsley JJ, Rudra JS.   +5 more
europepmc   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

Shaping Antitumor Immunity with Peptide Vaccines: Implications of Immune Modulation at the Vaccine Site. [PDF]

Vaccines (Basel)
Sarkar A, Rabinovich EP, Slingluff CL.
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Simultaneous efficacy of IL-15 and the HSP70 fragments in increasing immunostimulatory effects of a HIV-1 DNA vaccine candidate against SCR HIV-1. [PDF]

PLoS One
Fekri M, Bolhassani A, Movahedi M, Rahmati F.   +3 more
europepmc   +1 more source